We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone.
- Authors
Zagon, Ian S; Sassani, Joseph W; Immonen, Jessica A; McLaughlin, Patricia J
- Abstract
Background Ocular surface complications of type 2 diabetes are associated with reductions in tear production, increased corneal surface sensitivity, and delayed corneal re-epithelialization. This study examined the efficacy of topical application of the opioid antagonist naltrexone ( NTX) in reversing these diabetic-related ocular surface complications in mice. Methods The genetic db/db mouse model of type 2 diabetes, along with C57Bl/6 wild-type mice were investigated. Tear production was assessed by phenol red impregnated threads, and ocular surface sensitivity was measured using Von Frey filaments. Centrally located, circular corneal abrasions were created in mice and residual epithelial defects measured by fluorescein photography. Animals in each group received topical applications of drops of 10−5 M NTX in sterile Vigamox (Vigamox, Alcon Laboratories, Fort Worth, Texas, USA) or sterile Vigamox alone, and tear production, corneal sensitivity, and reepithelialization were monitored. Results In comparison to diabetic mice receiving vehicle only, db/db mice treated with one drop of NTX demonstrated a marked reversal in dry eye and ocular surface hypersensitivity within 1 h of one drop of NTX. Reversal of the complications in db/db mice usually lasted for 48-90 h. Corneal epithelial repair in db/db mice was enhanced following a regimen of three drops of NTX daily such that by 72 h, residual wounds were one third the size in db/db mice receiving NTX relative to diabetic mice receiving vehicle. Application of Vigamox alone had no effect. No adverse effects of NTX administration were noted in the cornea. Conclusions This is the first report of the efficacy of topical NTX in reversing corneal surface complications in type 2 diabetic mice.
- Subjects
TYPE 2 diabetes; DIABETES complications; LABORATORY mice; NALTREXONE; ALKALOIDS
- Publication
Clinical & Experimental Ophthalmology, 2014, Vol 42, Issue 2, p159
- ISSN
1442-6404
- Publication type
Article
- DOI
10.1111/ceo.12144